Duration and Tapering of Prednisolone Therapy
Once remission is achieved, taper prednisolone by 1 mg every 4 weeks until discontinuation, provided remission is maintained. This gradual tapering approach is the most strongly recommended strategy across multiple high-quality guidelines 1.
Initial Tapering Phase (First 4-8 Weeks)
After symptoms and inflammatory markers normalize, the initial tapering should proceed more rapidly:
- Reduce prednisolone to 10 mg/day within 4-8 weeks of achieving disease control 1
- This initial phase allows for faster dose reduction while the disease is well-controlled and inflammation has subsided
Maintenance Tapering Phase (After Reaching 10 mg/day)
Once you reach 10 mg/day, the tapering becomes more gradual:
- Decrease by 1 mg every 4 weeks (or use alternate-day schedules like 10/7.5 mg on alternating days if 1 mg tablets are unavailable) 1
- Alternative acceptable schedule: 1.25 mg decrements every 4 weeks or 2.5 mg every 10 weeks 1
- Continue this slow taper until complete discontinuation
Monitoring During Tapering
Follow-up schedule should be:
- Every 4-8 weeks during the first year 1
- Every 8-12 weeks during the second year 1
- More frequently if relapse occurs or during critical tapering phases
At each visit, assess:
- Disease activity markers (clinical symptoms and inflammatory markers like ESR/CRP)
- Glucocorticoid-related adverse events
- Risk factors for relapse
Managing Relapses During Tapering
If relapse occurs during tapering:
- Increase prednisolone back to the pre-relapse dose (the dose at which the patient was last stable) 1
- Decrease gradually within 4-8 weeks back to the dose at which relapse occurred
- Resume the slow 1 mg/4 weeks taper from that point
Total Duration of Therapy
While no fixed duration can be mandated, the evidence suggests:
- Most patients require 12-24 months of therapy to achieve sustained remission 1
- The 2015 EULAR/ACR guidelines strongly recommend using the minimum effective individualized duration 1
- Total cumulative dose using this tapering strategy typically ranges from 1,800-2,400 mg over 14-18 months 2
Special Considerations
Single daily dosing is preferred over divided doses, except in special situations like prominent night pain when tapering below 5 mg/day 1
Consider adding methotrexate (7.5-10 mg/week) early in patients with:
- High risk of relapse or prolonged therapy
- Comorbidities that increase glucocorticoid-related adverse event risk (diabetes, osteoporosis, glaucoma)
- Relapse despite appropriate glucocorticoid management 1
Common Pitfalls to Avoid
- Tapering too rapidly below 10 mg/day increases relapse risk significantly
- Fixed rigid schedules without individualization based on disease activity and patient factors
- Stopping abruptly after long-term therapy—always taper gradually 3
- Ignoring glucocorticoid-related adverse events during prolonged therapy—implement bone protection, peptic ulcer prophylaxis as indicated 4
The key principle is that tapering must be individualized based on continuous monitoring of disease activity, laboratory markers, and adverse events, but the 1 mg/4 weeks schedule after reaching 10 mg/day provides the optimal balance between preventing relapse and minimizing glucocorticoid exposure 1.